Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adipose Derived Mesenchymal Stem Cells in ALS
NCT02492516Phase 1Completed
- Sponsor
- Royan Institute
- Start
- Sep 2014
- Primary completion
- Mar 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in amyotrophic lateral sclerosis (ALS), sponsored by Royan Institute. Primary endpoints: Fever at 72 hours and Unconsciousness at 72 hours. Started Sep 2014; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02492516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492516.